Mollet Cave is a small cave situated in Serinyà (north-east Iberian Peninsula). It was excavated in 1947-48, 1958 and 1972 by Josep M. Corominas. An archaic human molar comes from its base layer (Layer 5). Up till now, this layer has only been dated based on a relative and imprecise chronology of macromammals and the archaeostratigraphic evidence from the early excavations. Recent excavations, conducted between 2001 and 2005, have made it possible to ascertain more precisely the archaeological and palaeontological contents of Mollet Cave, gather microvertebrates, and collect samples for radiometric dating. The aim of this paper is to present the absolute dating of Layer 5, as well as its palaeo environmental and climatic characterisation. The macromammal assemblage seems to have been the result of accumulations produced by the most abundant carnivore, the hyena, which would have used the cave as a den. The results obtained using uranium-series disequilibrium dating ascribe to Layer 5 an age of ca. 215 ka (thousands of years ago), which would correspond to MIS 7. The faunal association suggests a landscape formed by an open and humid woodland characteristic of an interstadial phase, which would have been an environment well suited to sustaining both hyenas and human groups.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jhevol.2012.01.009 | DOI Listing |
J Hum Evol
December 2024
Institut de Recerca Històrica, Universitat de Girona, Ferrater i Mora, 1, 7004, Girona, Spain.
Background: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab (anti-IL-6 receptor monoclonal antibody) or anakinra (anti-IL-1 receptor antagonist) with usual care for those with inflammation refractory to initial treatment.
Methods: We did this randomised, controlled, open-label, platform trial in 51 hospitals in the UK.
Lancet Diabetes Endocrinol
December 2023
Background: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.
Methods: In the randomised, controlled, open-label RECOVERY trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19.
Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!